The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's LTRN LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central Nervous System.
- LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
- Related content: Benzinga's Full FDA Calendar.
- The FDA has previously granted LP-184 Orphan Drug status for pancreatic cancer and malignant glioma, including glioblastoma multiforme.
- Price Action: LTRN shares are up 11.1% at $6.80 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in